Share on LinkedInShare on LinkedIn

ARTICLE · 21 JANUARY 2011

Intellectual Property Update - January 2011

In a recent decision, AstraZeneca LP v. Apotex, Inc., No. 2009-1381 (Fed. Cir. Nov. 1, 2010), the Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the District of New Jersey’s grant of a preliminary injunction barring defendant Apotex from distributing the generic version of AstraZeneca’s Pulmicort®.

United StatesIntellectual Property

The Federal Circuit Affirms the New Jersey District Court's Preliminary Injunction to Bar Generic Drug Pulmicort

In a recent decision, AstraZeneca LP v. Apotex, Inc., No. 2009-1381 (Fed. Cir. Nov. 1, 2010), the Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the District of New Jersey's grant of a preliminary injunction barring defendant Apotex from distributing the generic version of AstraZeneca's Pulmicort®.

Apotex filed an Abbreviated New Drug Application (ANDA) seeking FDA approval to manufacture and sell a generic version of Pulmicort, a budesonide inhalation suspension developed and patented by AstraZeneca for treating asthma. AstraZeneca then filed a declaratory judgment action and moved to enjoin Apotex from distributing the generic drug. The district court granted AstraZeneca's request for a preliminary injunction, finding that Apotex would not likely prevail at trial in proving the AstraZeneca claims were invalid and that

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from